Bipartisan Bill Would Codify Trump's Psychedelic Therapy Executive Order Into Federal Law

A bipartisan group of lawmakers has introduced legislation to cement President Trump's executive order on psychedelic therapy into permanent federal law, a move that could fundamentally reshape how the United States treats addiction and mental health disorders.

The Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy (IBOGAINE) Act, introduced July 1 by Representatives Lou Correa (D-CA), Morgan Luttrell (R-TX), Jack Bergman (R-MI), and Michael McCaul (R-TX), aims to ensure that the federal government's accelerated support for psychedelic research survives beyond the current administration.

From Executive Action to Legislative Framework

President Trump's Executive Order 14401, signed in April, directed federal agencies to expedite research and access to psychedelic drugs for treating serious mental illness. The order represented a dramatic shift in federal drug policy, acknowledging the therapeutic potential of substances that remain classified as Schedule I controlled substances.

However, executive orders can be reversed by future administrations. The IBOGAINE Act would transform these directives into statutory law, creating a durable framework for continued research and, eventually, clinical access.

"Our veterans put their lives on the line to defend our country, and far too many come home with invisible wounds," said Representative Correa, who has championed psychedelic therapy access alongside Representative Bergman for several years. "They deserve access to every effective resource available to help treat PTSD and support their recovery."

The Veteran Imperative

The legislation's focus on veterans reflects both the urgency of the mental health crisis among former service members and the political strategy that has made psychedelic therapy a rare bipartisan issue. An estimated 17 veterans die by suicide each day in the United States, according to Department of Veterans Affairs data, and traditional treatments have failed to stem the tide.

For veterans suffering from treatment-resistant PTSD and addiction, psychedelic-assisted therapy currently requires traveling overseas to countries where such treatments are legally available. This barrier has created a two-tiered system where those with financial resources can access potentially life-saving treatments while others remain trapped in cycles of suffering.

Representative Luttrell, a veteran himself, spoke directly to this experience: "Psychedelic therapy has helped me and countless other veterans, improving our lives for the better. As we fight to combat our veteran suicide crisis, this breakthrough must be available to the men and women who served our nation."

The Science Behind the Policy

The legislative push builds on mounting clinical evidence for psychedelic therapies. A 2024 study from Stanford University School of Medicine found that participants who received ibogaine treatment experienced remarkable reductions in mental health symptoms: 88% decrease in PTSD symptoms, 87% reduction in depression, and 81% improvement in anxiety after just one month.

These findings align with decades of observational research suggesting that certain psychedelic compounds can catalyze profound psychological healing when administered in controlled therapeutic settings. Unlike traditional psychiatric medications that require daily dosing and often provide only symptomatic relief, psychedelic therapies appear to address root causes of psychological distress through neuroplasticity and enhanced emotional processing.

For individuals struggling with substance use disorders, these treatments represent a potential paradigm shift—moving from chronic disease management toward genuine recovery and transformation.

Implementation Challenges Ahead

Despite bipartisan momentum, significant hurdles remain. The legislation must navigate a crowded congressional calendar and potential opposition from lawmakers wary of any policy perceived as drug liberalization. Additionally, the Drug Enforcement Administration maintains strict controls on Schedule I substances, and regulatory pathways for medical use remain complex.

The FDA has already approved the first U.S. clinical trial of ibogaine for alcohol use disorder, a milestone that could provide crucial data for future regulatory decisions. However, full approval for clinical use likely remains years away, requiring extensive Phase II and III trials to establish safety and efficacy.

Representative Bergman emphasized the need for congressional action beyond the current bill: "Executive action alone is not enough. An Executive Order cannot rewrite federal law, and it can be reversed by a future administration. Congress must continue to act to streamline FDA approvals, address outdated restrictions, and guarantee the VA fully implements these policies."

A Shifting Political Landscape

The IBOGAINE Act represents more than specific policy—it signals a fundamental reassessment of how American society approaches mental health and addiction. For decades, the War on Drugs framework dominated federal policy, treating substance use primarily as a criminal justice issue rather than a public health concern.

The emergence of bipartisan psychedelic legislation suggests that this paradigm is eroding. Conservative Republicans, including former Texas Governor Rick Perry and Texas Representative Dan Crenshaw, have joined progressive Democrats in supporting research access, united by the urgency of the veteran suicide crisis and the promise of evidence-based treatments.

This coalition reflects a broader cultural shift as well. As research accumulates and personal testimonials proliferate, stigma surrounding psychedelic substances is gradually giving way to scientific curiosity and therapeutic hope. For families who have watched loved ones struggle with treatment-resistant conditions, these changes cannot come soon enough.

What Comes Next

The IBOGAINE Act now moves to committee consideration, where it will face scrutiny from lawmakers and testimony from experts. If successful, it could pave the way for additional legislation addressing regulatory barriers, insurance coverage, and VA implementation.

For the millions of Americans suffering from PTSD, depression, and addiction, the bill represents a potential lifeline—a recognition that healing is possible and that federal policy should facilitate rather than obstruct access to effective treatments.

As Representative McCaul stated: "We have a profound moral obligation to help these heroes heal from their wounds, both seen and unseen."

Whether that obligation translates into lasting legislative change will depend on the continued advocacy of veterans, families, and policymakers willing to look beyond outdated drug war frameworks toward a future where recovery is truly within reach.